Dr Pablo Menéndez talks to ecancer at the European School of Haematology (ESH) meeting: International Conference on Acute Lymphoblastic Leukaemia about the MLL rearrangement in paediatric acute lymphoblastic leukaemia (ALL).
He describes the origin of this disease, including the generation of this translocation using in vivo methods and its associated consequences.
Dr Menéndez also discusses how these mutations can be targeted both before and after relapse and how the genetic differences between ALL subtypes.
He concludes by stating the possible therapeutic approaches for this disease - including the inhibition of NG2 to cause a delay in relapse.
ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.